Adrenocortical secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Template:AR Mohammed Abdelwahed M.D[2] Template:Adrenocortical carcinoma secondary prevention

Overview

Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years and surveillance intervals may be increased to 6 months for the next 5 years. Surveillance includes cross-sectional imaging of chest, abdomen, and pelvis, the use of FDG-PET for lesions of an unclear nature, laboratory evaluation for steroid hormones and evaluation of side effects in case of adjuvant mitotane therapy.

Adrenocortical carcinoma secondary prevention

Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. Surveillance intervals may be increased to 6 months for the next 5 years. Surveillance should also include: Cross-sectional imaging of chest, abdomen, and pelvis The use of FDG-PET for lesions of an unclear nature Laboratory evaluation for steroid hormones Evaluation of side effects is also important in case of adjuvant mitotane therapy